We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$5.04
$-0.12
(-2.33%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
3,533.9M
52-Week High
16.76
52-Week Low
2.52
Average Volume
0.96M
Dividend Yield
--
P/E Ratio
--
Market Capitalization3,533.9M
52-Week High16.76
52-Week Low2.52
Average Volume0.96M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Ticker Report
12days ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) Director Financial Lp Qvt sold 5,656,081 shares of the stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $4.75, for a total transaction of $26,866,384.75. Following the transaction, the ...
Globe Newswire
19days ago
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37th Annual Meeting of The Society for ...
Zolmax
30days ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) CEO Matthew Gline sold 19,276 shares of the stock in a transaction on Tuesday, October 25th. The shares were sold at an average price of $4.40, for a total value of $84,814.40. Following the sale, the chief executive officer now owns 1,164,009 shares in...
Zolmax
30days ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) COO Eric Venker sold 15,922 shares of the companys stock in a transaction that occurred on Tuesday, October 25th. The stock was sold at an average price of $4.40, for a total transaction of $70,056.80. Following the completion of the ...
Ticker Report
2 months ago
Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) CEO Matthew Gline sold 21,053 shares of Roivant Sciences stock in a transaction on Friday, September 23rd. The stock was sold at an average price of $3.07, for a total value of $64,632.71. Following the transaction, the chief executive officer ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$5.04
$-0.12
(-2.33%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00